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Background. We sought to characterize the relationship between individual group B streptococcus (GBS) colonization and pre-
discharge postpartummethicillin resistant Staphylococcus aureus (MRSA) infection in United States women delivering at term.We
also sought to examine the association between hospital GBS colonization prevalence andMRSA infection.Materials andMethods.
Data was from the Nationwide Inpatient Sample, a representative sample of United States community hospitals. Hierarchical
regression models were used to estimate odds ratios adjusted for patient age, race, expected payer, and prepregnancy diabetes and
hospital teaching status, urbanicity, ownership, size, and geographic region.We usedmultiple imputation formissing covariate data.
Results. There were 3,136,595 deliveries and 462 cases of MRSA infection included in this study. The odds ratio for individual GBS
colonization was 1.2 (95% confidence interval: 0.9 to 1.5). For a five-percent increase in the hospital prevalence of GBS colonization,
the odds ratio was 0.9 (95% CI: 0.1 to 5.6). Conclusions. The odds ratio estimate for the association of hospital GBS prevalence
with MRSA infection is too imprecise to make conclusions about its magnitude and direction. Barring major bias in our estimates,
individual GBS carriage does not appear to be strongly associated with predischarge postpartumMRSA infection.
1. Introduction
Staphylococcus aureus is a gram positive coccus that can
cause asymptomatic colonization, as well as a wide variety
of infections in humans, including skin lesions, cellulitis,
pneumonia, necrotizing fasciitis, wound infections, sepsis,
meningitis, endocarditis, urinary tract infections, and toxic
shock syndrome [1, 2]. Methicillin-resistant Staphylococcus
aureus (MRSA) refers to S. aureus strains that have devel-
oped resistance to 𝛽-lactam antibiotics, including penicillins,
cephalosporins, and carbapenems [3].
Group B streptococcus (GBS, also known as Streptococcus
agalactiae) is thought to cause asymptomatic colonization in
10–30% of late-term pregnant women. Maternal colonization
with GBS is a risk factor for early neonatal GBS disease,
which may be fatal or cause permanent disability. Because
of this risk, the Centers for Diseases Control and Prevention
recommend that all pregnant women be screened for GBS
colonization between 35 and 37 weeks of gestation and that
women who are found to be carriers receive prophylactic
intrapartum antibiotic treatment (IPA) with penicillin or
ampicillin (both 𝛽-lactam antibiotics) [4].
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There are two primary reasons to suspect that there
may be a correlation between GBS colonization and MRSA
infection. The first is the use of intrapartum antibiotic
prophylaxis, which is given to an estimated 87% of women
who test positive for GBS prenatally [10]. While antibiotic
exposure is an established risk factor for MRSA infection
[11], the question of whether or not IPA causes antibiotic
resistance is a controversial one. While most isolates of
GBS are sensitive to penicillin and ampicillin, isolates with
increased minimum inhibitory concentrations and in vitro
resistance have been reported [4]. Aside froma single hospital
based case-control study (described below) we could find no
studies that examined whether women who have received
IPA are at greater risk of subsequent drug resistant infections.
However, several studies have found an association between
IPA and neonatal infections with drug resistant organisms
[12–14].
The second reason to suspect an association betweenGBS
colonization and postpartum MRSA infection is that GBS
colonized women may be more likely to be colonized with
MRSA. A number of studies have investigated the association
between rectovaginal carriage of GBS and S. aureus orMRSA
carriage. Two studies reported increased odds of S. aureus
colonization, and one study found increased odds of MRSA
carriage in GBS positive women [5, 6, 15]. Another study
found increased odds of GBS carriage in women colonized
with MSSA relative to those with no S. aureus carriage and
decreased odds of GBS carriage in women colonized with
MRSA relative to those colonized with MSSA but could not
detect an association between GBS and MRSA using women
not colonized with S. aureus as the reference group [8]. For
more details on the literature regarding GBS and MRSA
carriage in pregnant women, see Table 1.
We could find only one study that examined the rela-
tionship between GBS carriage and invasiveMRSA infection.
A case control study of an outbreak of MRSA skin and soft
tissue infections in a New York city hospital found no GBS
colonization among 8 cases, while 11 of 46 controls were
colonized (𝑃 = 0.03) [16]. That study also found that cases
were less likely to have received IPA than controls (although
the association was not significant at the 𝛼 = 0.05 level).
However, this study was limited to a single outbreak in one
hospital and may not be representative of postpartumMRSA
infection nationwide.
We sought to examine the relationship between GBS
colonization and MRSA infection prior to discharge in US
maternity inpatients delivering at term. We also sought to
examine the association between hospital GBS colonization
prevalence and predischarge MRSA infection. If an associ-
ation between GBS carriage and invasive MRSA infections
exists, the clinical implications would be dependent on the
mechanism. If the association is due to increased prevalence
of MRSA colonization in GBS carriers, it may be prudent to
consider the costs and benefits of targeted MRSA screening
and decolonization in GBS positive women. If the association
is due to the use of IPA prophylaxis, then the risk of MRSA
infections in the mother should be weighed against the
benefits to the infant.
2. Materials and Methods
2.1. Data Source. The Nationwide Inpatient Sample (NIS)
is a representative sample of approximately 20% of US
community hospitals. Among hospitals included in the NIS,
all inpatient discharges are reported. The NIS contains both
hospital and patient level data. For patient level data, there
is one record for each inpatient admission. Thus, one indi-
vidual may contribute to multiple observations. The NIS is
administered by the Healthcare Cost and Utilization Project
(HCUP), a Federal-State-Industry partnership sponsored by
the Agency for Healthcare Research and Quality (AHRQ). A
complete list of agencies that contribute data to HCUP can be
found at http://www.hcup-us.ahrq.gov/partners.jsp?NIS.
Because this study used a preexisting, deidentified, pub-
licly available dataset, it was exempt from review by the
Institutional Review Board of the University of California,
Los Angeles.
2.2. Study Group. For this analysis, we included women in
the NIS for years 2005 through 2008 who were admitted
for delivery of an infant (Diagnosis Related Group 24 370–
375) to a hospital with more than 50 deliveries per quarter.
We excluded women with documented preterm delivery or
inadequate prenatal care to minimize the number of women
who had not been screened for GBS colonization.
2.3. Outcome Assessment. The outcome of interest was inva-
sive MRSA infection prior to discharge after hospitalization
for the delivery of an infant. In 2008, several new ICD-
9 CM codes indicating MRSA infection or carriage were
introduced including 038.12 (MRSA septicemia), 482.42
(methicillin resistant pneumonia due to S. aureus), and 041.12
(MRSA in conditions classified elsewhere and of unknown
site), which are used to define invasive MRSA infections in
2008 admissions. Prior to 2008, invasive MRSA infection
is defined by presence of ICD-9 codes 482.41 (S. aureus
pneumonia), 038.11 (S. aureus septicemia), or 041.11 (S. aureus
in conditions classified elsewhere and of unknown site) along
with code V09.0 (infection with microorganisms resistant to
penicillins).
2.4. Exposure Assessment. The primary exposure of interest
in this analysis is carriage of or infection with GBS. Carriers
of GBS were identified using ICD-9 CM codes 041.02 (group
B streptococcal infection) and V02.51 (carrier or suspected
carrier of group B streptococcus).
Due to the communicable nature of MRSA and its
propensity to spread in hospital settings, the exposure status
of other women in the same hospital may also put patients at
risk. Therefore, the prevalence of GBS carriage in delivering
women was also calculated for each hospital.
2.5. Covariates. Patient level covariates were race, age,
expected payer (used as a proxy of socioeconomic status), and
prepregnancy diabetes.
Hospital level variables used to create the sampling
frame for the NIS were also included in our models. These
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Table 1: Associations between group B streptococcus colonization and S. aureus colonization in pregnant women.
Outcome Study OR 95% confidence interval
All S. aureus
Andrews et al., 2008 [5] 1.6 1.4–1.9
Chen et al., 2006 [6] 2.1 1.7–2.5
Creech et al., 2010 [7] NR Includes 1
MRSA
Andrews et al., 2008 [5] 2.2 1.6–1.8
Chen et al., 2007 [8] 0.1∗ 0.0–0.7
0.4∗∗ 0.0–3.5
Creech et al., 2010 [7] NR Includes 1
Reusch et al., 2008 [9] 0.6 0.1–5.0
MSSA Chen et al., 2007 [8] 4.5 1.7–11.0
NR: not reported; ∗reference group is MSSA positive women; ∗∗reference group is S. aureus negative women, crude OR.
variables were teaching status, urbanicity, ownership, size,
and geographic region. Definitions of hospital size, owner-
ship, and regions can be found in the Introduction to the
HCUP Nationwide Inpatient Sample, at http://www.hcup-
us.ahrq.gov/db/nation/nis/NIS Introduction 2008.jsp [17].
2.6. Statistical Analysis. To estimate the association between
GBS status and MRSA infection, we analyzed the data using
hierarchical logistic regression with a random intercept.
Multiple imputation of missing variables was conducted
using PROCMI in SAS version 9.2. Individual level covariates
were imputed using amodel that contained an indicator vari-
able for the hospital. Hospital level variables were imputed at
the hospital level, such that all patients in a given hospital
have the same imputed value within an imputation. For
comparison, the analysis was repeated without imputation.
Analyses were done using Statistical Analysis Software
(SAS) version 9.2 and Stata version 12.
2.7. Bias Analysis. Obesity appears to be a risk factor for post-
partum infection and MRSA skin and soft tissue infections
[18–20]. GBS colonization may be more common in obese
women; Stapleton et al. found amodest increased risk of GBS
colonization with increasing BMI [21].
While the NIS contains a variable for obesity, only 2.2%
of women in the sample were recorded as being obese.
In contrast, 30% of women aged 20 to 39 in the 2005-
2006 National Health and Nutrition Examination Survey
and 18% of women aged 18 to 42 in the 2009 California
Health Interview Survey were obese [22, 23]. This led us to
suspect that the obesity measure in the NIS is unreliable and
inadequate to control for possible confounding by obesity.
Probabilistic bias analysis for confounding by obesity
was conducted by directly adjusting calculated measures of
association, using the technique detailed by Lash et al. [24].
Five thousand iterationswere run.Theprior for the odds ratio
for the effect of obesity onMRSA infection is lognormal, with
95% prior limits at 1.0 and 3.0. The prior for the proportion
of obesity women among GBS colonized women is beta
distributed, with 𝛼 = 10.47 and 𝛽 = 41.87. This corresponds
to a unimodal distribution with a mean of 0.2 and 95% prior
limits of 1% and 32%. The prior for the proportion of obese
amongGBS negative women is beta distributed with 𝛼 = 1.76
and 𝛽 = 9.99, corresponding to a unimodal distribution with
a mean of 0.15 and 95% prior limits of 2% and 39%.
Due to recentering and rescaling of hospital GBS preva-
lence, the odds ratio compares the odds ofMRSA infection in
a hospital with a prevalence of 20% to the odds of infection
in a hospital with a prevalence of 15%. To create expected
prevalence of obesity for the “exposed” and “unexposed”
group, we took a weighted average of the numbers drawn
from the beta distributions for obesity prevalence among
GBS positive and GBS negative women. For 15% hospital
GBS prevalence, the value drawn from the GBS negative
distribution was assigned a weight of 0.85, and the value
drawn from the GBS positive distribution was assigned a
weight of 0.15. For 20% hospital prevalence, the weights were
0.8 for the GBS negative distribution and 0.2 for the GBS
positive distribution.
3. Results
A total of 3,136,595womenwith no record of pretermdelivery
or inadequate prenatal care delivered infants in hospitals
with 50 or more deliveries per quarter. Among these women,
there were 500,225 documented cases of GBS colonization
(16%) and 462 documented cases of MRSA infection. Table 2
displays the univariate distributions of the outcome and
covariates by GBS colonization status.
We were unable to determine the site of MRSA infection
in just over half of cases.Themost common documented sites
of infection were skin (32% of infections), urinary tract (7%),
other genitourinary sites (5%), and wounds (3%).
The results of the multivariable analysis, including bias
adjustment for unmeasured confounding by obesity, are
given in Table 3. The adjusted odds ratio for individual GBS
colonization was 1.2, and the 95% confidence interval was
0.9 to 1.5. The OR for hospital GBS colonization prevalence
was 0.9, and the 95% CI was 0.1 to 5.6. For comparison, a
model was run without imputation of missing values, using
only complete records. The change in the odds ratio and
confidence interval for individual colonization was negligible
while the odds ratio for hospital GBS prevalence was 1.3, and
the 95% confidence limit was 0.2 to 11.3.
In the bias analysis, the mean value of the bias factor (the
ratio of the biased to the adjusted odds ratio) for individual
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Table 2: Patient and hospital characteristics by GBS status and prevalence.
Variable Category Patient GBS status Hospital GBS prevalence
Noncarrier Carrier ≤15% >15%
Total number 2,636,370 500,225 1,341,521 3,136,595
MRSA infection (%) 0.01 0.02 0.02 0.01
Race∗ (%)
White 39.04 40.12 35.69 41.85
Black 8.20 12.02 7.67 9.66
Hispanic 19.58 14.61 26.71 12.86
Asian 3.87 3.92 3.70 4.01
Other 4.29 3.97 4.23 4.24
Age∗ (%)
<20 9.81 10.06 11.60 9.26
20–29 52.29 51.95 54.31 50.71
30–39 35.12 35.44 31.55 37.09
40+ 2.67 2.54 2.43 2.89
Expected payer∗ (%)
Private insurance 51.93 55.39 47.65 57.21
Medicaid 40.98 38.63 44.03 36.59
Other payer 6.93 5.85 8.15 5.73
Diabetes (%) 0.72 0.77 0.71 0.74
Teaching hospital (%) 45.24 48.25 40.48 49.64
Urban hospital (%) 89.20 90.53 86.80 91.36
Hospital size∗† (%)
Small 11.69 12.06 11.14 12.20
Medium 25.76 25.43 27.35 24.48
Large 62.42 62.39 61.35 63.22
Hospital control† (%)
Private or public, collapsed 57.21 60.52 51.61 62.32
Public 7.05 6.61 7.44 6.63
Private, nonprofit 21.24 20.37 22.18 20.29
Private, investor owned 10.72 9.33 13.74 8.08
Private, collapsed 3.66 3.04 4.87 2.58
Hospital region (%)
Northeast 16.39 17.67 13.42 18.97
Midwest 20.47 21.49 18.03 22.57
South 37.81 37.11 38.69 36.95
West 25.33 23.73 29.85 21.51
∗Percentages may not add to 100 due to missing values.
†See Introduction to the HCUP Nationwide Inpatient Sample for an explanation of variable categories.
Table 3: Multivariable adjusted∗ odds ratio and 95% confidence intervals for the association of individual GBS carriage and hospital GBS
prevalence with early postpartumMRSA infection.
Analysis Exposure Odds ratio 95% CI
Without imputation of missing values Individual GBS colonization 1.2 0.9–1.5
Hospital prevalence of GBS colonization∗∗ 1.3 0.2–11.3
With multiple imputation of missing values Individual GBS colonization 1.2 0.9–1.5
Hospital prevalence of GBS colonization∗∗ 0.9 0.1–5.6
With multiple imputation and bias adjustment for obesity Individual GBS colonization 1.1 0.8–1.5
Hospital prevalence of GBS colonization∗∗ 0.9 0.1–5.6
∗All models adjusted for patient age, race, expected payer, and prepregnancy diabetes and hospital teaching status, urbanicity, bed size, ownership, and
geographic region.
∗∗Odds ratio is for a 5% increase in the prevalence of GBS colonization.
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GBS carriage was 1.05, and the variance of the log bias factor
was 0.01.The bias adjusted median odds ratio was 1.1, and the
95% simulation interval was 0.8–1.5. For the odds ratio for
hospital GBS prevalence, the distribution of the bias control
factor had a mean very nearly equal to one (1.003) and a
variance very nearly equal to zero (3.2 × 10−5); thus the bias
adjusted odds ratio and 95% simulations interval are equal to
the unadjusted estimate and 95% confidence interval.
4. Discussion
While other studies (noted above) have investigated the
relationship between GBS carriage and MRSA colonization
in pregnant and laboring women, we could identify no other
studies that examined the risk of invasiveMRSA infection in a
nationally representative sample. Thus, our results cannot be
interpreted in the context of previouswork,making it difficult
to draw comparative conclusions. Before considering the
amount of evidence this study provides, several limitations
should be considered.
A major weakness of this study is that followup is
limited to the predischarge period, as the NIS only includes
information on diagnoses that occurred prior to discharge
after delivery of an infant and contains no mechanism to
track patients who are readmitted. Because the predictors
of predischarge infection may not be representative of the
predictors of postpartum MRSA as a whole, these findings
should not be generalized to the postdischarge period. Recog-
nition of this limitation of generalizability is important, since
the majority of postpartum infections are diagnosed after
hospital discharge [25].
There is also potential formisclassification of the outcome
variable. Diagnosis of MRSA infection typically requires
antibiotic susceptibility testing, which may not be performed
in some cases, particularly when an infection resolves spon-
taneously. It is also possible that diagnosed MRSA infections
may not be correctly coded in discharge data. Schweizer et al.
conducted a validation study of the use of discharge data to
detect MRSA infections, using medical record review as the
gold standard.They found excellent specificity (99%) but low
sensitivity (20%) [26].
An additional limitation of this analysis is the possibil-
ity of incomplete reporting of the exposure variable. The
reported prevalence of GBS carriage in delivering women
who do not have diagnostic codes for premature labor or
inadequate prenatal care is 16%. This falls within the CDC’s
reported prevalence of 10% to 30% [4]. However, the NIS is
constructed from data gathered for the purposes of hospital
billing, and discharge data may underreport diagnoses and
conditions that are not likely to result in additional com-
pensation for the hospital. It is also possible that inadequate
prenatal care and preterm birth (particularly late preterm
birth, where management of the labor and the neonate differs
a little from term birth) are underreported. We could find
no validation studies of the use of administrative data to
determine GBS colonization or infection status. However,
validation of hospital discharge data for other pregnancy
conditions has generally shown very high specificity, but
sometimes low sensitivity [27].
As we expect the specificity of our exposure and out-
come variable to be excellent, we would not expect bias
from misclassification as long as errors in exposure and
outcome status were nondifferential and uncorrelated [28].
However, we cannot rule out the possibility of differential
misclassification. Of particular concern is the possibility of
positive correlation of exposure and outcome misclassifica-
tion. Table S1 (see Supplementary Material available online
at http://dx.doi.org/10.1155/2014/515646) shows the possible
values of the odds ratio under different values of sensitivity
of the outcome, given the recorded exposure status.
The limitations discussed above could be substantially
reduced by examining the relationship between GBS col-
onization and MRSA infection in a setting where infor-
mation from postpartum readmissions and outpatient care
(particularly prenatal care visits) is available. This would
allow extension of the follow-up period beyond the hospi-
talization for delivery and permit restriction of the study
group to women who are known to have been screened
for GBS colonization. A staff model health maintenance
organization (HMO), where patients receive nearly all of
their care from a centralized organization, would be an
ideal setting for further examination of these research
questions.
The primary strength of this analysis lies in the large
sample size, which provides adequate power to examine the
rare outcome of postpartum MRSA infection. The sample
is also designed to be representative of the population of
US nonfederal hospitals. As all patients within participating
hospitals were sampled, there is no potential for selection bias
at the patient level.
5. Conclusion
This analysis did not detect an association between either
GBS colonization at the hospital level or hospital prevalence
of GBS colonization and predischarge MRSA infection in
women admitted for delivery of an infant. Furthermore, given
the assumptions of our data model (including absence of any
major source of bias) our data are compatible with, at most, a
modest association between individual GBS carriage and risk
of invasive MRSA infection.
The 95% confidence interval for the association of hos-
pital GBS prevalence and predischarge MRSA infection is
very wide (0.1 to 5.6). While we were unable to detect a
relationship, our results are too imprecise to rule out large
effects in either direction, even if we assume no uncontrolled
bias.
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